Distribution patterns of intramyocellular and extramyocellular fat by magnetic resonance imaging in subjects with diabetes, prediabetes and normoglycaemic controls (2021) Kiefer LS, Fabian J, Rospleszcz S, Lorbeer R, Machann J, Kraus MS, Roemer F, et al. Journal article Undertreatment of cardiovascular risk factors in the type 1 diabetes exchange clinic network (United States) and the prospective diabetes follow-up (Germany/Austria) registries (2020) Shah VN, Grimsmann JM, Foster NC, Dost A, Miller KM, Pavel ME, Weinstock RS, et al. Journal article Impact of microvascular disease on cardiovascular outcomes in type 2 diabetes: Results from the LEADER and SUSTAIN 6 clinical trials (2020) Verma S, Bain SC, Honoré JB, Mann J, A. Nauck M, E. Pratley R, Rasmussen S, et al. Journal article Cardiovascular and renal outcomes by baseline albuminuria status and renal function: Results from the LEADER randomized trial (2020) Mosenzon O, Bain SC, Heerspink HJL, Idorn T, Mann J, Persson F, Pratley RE, et al. Journal article Health-related quality of life in people with type 2 diabetes participating in the LEADER trial (2019) Nauck MA, Buse JB, Mann J, Pocock S, Bosch-Traberg H, Frimer-Larsen H, Ye Q, Gray A Journal article LEADER 2: baseline calcitonin in 9340 people with type 2 diabetes enrolled in the Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial: preliminary observations (2015) Daniels GH, Hegedus L, Marso SP, Nauck MA, Zinman B, Bergenstal RM, Mann J, et al. Journal article